RxDoctor Payments DataLook up a doctor →

Justin Spaulding, DO

Glaucoma Specialist · Medford, ORNPI 1013259167

Payments from drug & device makers

$309,574in general payments, 2019–2025

Across 133 payments — averaging $2327.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon Research LLC$241K
  • Bausch & Lomb Americas Inc.$64K
  • Nova Eye, Inc.$2K
  • Alcon$1K
  • AbbVie$257
  • Sun Pharmaceutical Industries Inc.$228
  • plus $1K from 17 others

What the payments were for

  • Consulting fees$62,00090%
  • Travel & lodging$2,8554%
  • Food & beverage$3,9656%
  • Gifts$450%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Oregonto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$1,441,318
Medicare patients
1,454
Services billed
254,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate877$45,191
MieboPerfluorohexyloctane/Pf45$33,922
VyzultaLatanoprostene Bunod56$27,325
SimbrinzaBrinzolamide/Brimonidine Tart110$23,340
RocklatanNetarsudil Mesylat/Latanoprost41$18,030
LumiganBimatoprost25$16,720
Latanoprost1,167$15,252
RestasisCyclosporine24$14,311
Travoprost89$10,695
Ketorolac Tromethamine866$10,133
Ofloxacin836$8,982
Timolol Maleate730$7,756
Methazolamide11$5,170
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat260$4,147
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol20$3,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Miebo, Vyzulta$63,509$61,247101 claims
AbbVieLumigan, Restasis$257$31,03149 claims
AlconSimbrinza$1,063$23,340110 claims
Aerie Pharmaceuticals, Inc.Rocklatan$65$18,03041 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Oregonon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Medford

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →